VISIPAQUE 320 MG I/ML

Indications

• Coronary angiography
• CT imaging
• Angiographic procedures

Dosage

Children: Refer to the BNF for Children for appropriate dosing information in paediatric patients.

Adults: Refer to the BNF for detailed dosing guidance based on the specific procedure and patient condition.

Mechanism of action

Iodixanol, as an organic iodine compound, attenuates x-rays as they pass through the body. The opacity produced is directly proportional to the concentration and volume of the iodinated contrast agent within the x-ray path. This property allows for the visualization of internal structures until significant hemodilution and elimination occur after intravascular administration.

Pharmacodynamics

Iodixanol is particularly useful in patients with renal dysfunction due to its lower toxicity profile compared to other contrast agents. It has an osmolality similar to that of blood (290 mOsm/kg H2O), which reduces the risk of adverse renal effects during imaging procedures.

Pharmacokinetics

After intravascular injection, iodixanol distributes rapidly in the vascular system. The contrast agent is primarily eliminated through renal excretion. The pharmacokinetics of iodixanol are influenced by the patient's renal function, and it is important to consider this when dosing and administering the agent.

Pregnancy

Iodixanol should only be used in pregnancy if the benefits outweigh the risks, as safety has not been established.

Breast-feeding

Iodixanol is excreted in breast milk. Caution is advised when administering to nursing mothers.

Storage

Store at room temperature, protected from light. Do not freeze.

Formulations

• Iodixanol 270 mg/ml solution for injection
• Iodixanol 320 mg/ml solution for injection

Mechanism of action

Organic iodine compounds attenuate x-rays as they pass through the body, thereby allowing the body structures containing iodine to be delineated in contrast to those structures that do not contain iodine. The degree of opacity produced by these compounds is directly proportional to the total amount (concentration and volume) of the iodinated contrast agent in the path of the x-rays. After intravascular administration, iodixanol makes opaque those internal structures in its path of flow, allowing their visualization until significant hemodilution and elimination occur. Intravascular injection of iodixanol opacifies those vessels in the path of flow of the contrast agent, permitting radiographic visualization of the internal structures until significant dilution and elimination occurs.

Pharmacodynamics

Iodixanol is a contrast agent commonly used during coronary angiography, particularly in individuals with renal dysfunction, as it is believed to be less toxic to the kidneys than most other intravascular contrast agents. It is an imaging contrast agent with the same osmolality as blood (290mOsm/kg H20).